Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852 is registered in ClinicalTrials.gov with Bolt Biotherapeutics, Inc. as lead sponsor.

NCT NCT06052852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Lead sponsor
Bolt Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 11, 2023
Completion date
August 1, 2025
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, colorectal cancer, head and neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, triple negative breast cancer